Leerink Partnrs Estimates AxoGen's Q2 Earnings (NASDAQ:AXGN)

AxoGen, Inc. (NASDAQ:AXGN - Free Report) - Leerink Partnrs dropped their Q2 2025 EPS estimates for shares of AxoGen in a report released on Monday, July 14th. Leerink Partnrs analyst M. Kratky now expects that the medical equipment provider will post earnings of ($0.04) per share for the quarter, down from their prior forecast of ($0.02). The consensus estimate for AxoGen's current full-year earnings is ($0.29) per share. Leerink Partnrs also issued estimates for AxoGen's FY2025 earnings at ($0.14) EPS, FY2027 earnings at $0.14 EPS, FY2028 earnings at $0.24 EPS and FY2029 earnings at $0.35 EPS.

Separately, Canaccord Genuity Group reduced their target price on shares of AxoGen from $26.00 to $24.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $24.50.

AxoGen Stock Performance

AxoGen stock traded down $0.35 during midday trading on Thursday, reaching $11.28. 676,057 shares of the stock traded hands, compared to its average volume of 612,727. The company has a current ratio of 4.28, a quick ratio of 2.65 and a debt-to-equity ratio of 0.63. The firm has a fifty day moving average price of $10.92 and a two-hundred day moving average price of $15.16. The firm has a market cap of $513.69 million, a price-to-earnings ratio of -75.19 and a beta of 1.04. AxoGen has a fifty-two week low of $7.34 and a fifty-two week high of $21.00.

Institutional Investors Weigh In On AxoGen

A number of large investors have recently made changes to their positions in AXGN. Driehaus Capital Management LLC raised its holdings in shares of AxoGen by 166.0% during the fourth quarter. Driehaus Capital Management LLC now owns 954,439 shares of the medical equipment provider's stock valued at $15,729,000 after acquiring an additional 595,579 shares during the period. First Light Asset Management LLC raised its holdings in shares of AxoGen by 10.2% during the fourth quarter. First Light Asset Management LLC now owns 4,506,795 shares of the medical equipment provider's stock valued at $74,272,000 after acquiring an additional 416,499 shares during the period. Invesco Ltd. raised its holdings in shares of AxoGen by 2,124.5% during the first quarter. Invesco Ltd. now owns 382,429 shares of the medical equipment provider's stock valued at $7,075,000 after acquiring an additional 365,237 shares during the period. Nuveen LLC acquired a new stake in shares of AxoGen during the first quarter valued at approximately $5,668,000. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of AxoGen during the fourth quarter valued at approximately $4,943,000. Institutional investors and hedge funds own 80.29% of the company's stock.

Insider Activity at AxoGen

In related news, Director Joseph A. Tyndall sold 20,062 shares of the business's stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $11.20, for a total value of $224,694.40. Following the sale, the director directly owned 15,345 shares in the company, valued at $171,864. The trade was a 56.66% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 2.78% of the stock is owned by insiders.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.